Medicus Pharma FY26 Q2 net loss widens 89.1% to $11.68 million

• Medicus Pharma posted a Q2 net loss of USD 11.68 million, widening from USD 6.18 million a year earlier.
• Operating loss widened to USD 11.48 million as total operating expenses rose 90.8% to USD 11.48 million.
• General and administrative costs climbed 43.6% to USD 6.57 million; R&D spending more than doubled to USD 4.91 million.
• Cash and cash equivalents were USD 15.17 million at June 30, with USD 10.02 million of restricted cash and working capital of USD 6.14 million.
• FDA issued a “Study May Proceed” letter for SkinJect’s SKNJCT-005 Phase 2b registrational trial; UAE DOH authorized Teverelix PRECISION-E2 Phase 2a.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-004230), on August 12, 2026, and is solely responsible for the information contained therein.